Clinical Trial Update: US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI)

View source ↗

Summary

A US post-marketing safety trial for LUMOXITI in hairy cell leukemia has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hairy Cell Leukemia

Drugs mentioned

• Lumoxiti (moxetumomab pasudotox-tdfk)

Snippet

Sponsor: AstraZeneca | Conditions: Hairy Cell Leukemia | Status: TERMINATED